Let's connect

Want to discuss your project or have any questions?

Target 2035 logo

Nuvisan joins IHI project LIGAND-AI to help advance AI-driven drug discovery through open science

21 January 2026

read more

Featured stories

Close up of business man in suit shaking hands

ALS takes ownership of Nuvisan

With the acquisition of the remaining 51% shares by ALS, we are excited to join the ALS group and contribute to strengthening its pharmaceutical footprint in Europe.

learn more
Nuvisan is the first Gyrolab® Certified CRO in the EU

Nuvisan is the first Gyrolab® certified CRO in the EU

Since March 2024, Nuvisan has become the first Gyrolab® certified CRO in the EU. 

learn more
Nuvisan receives $ 9.6m grant for a multi-target drug discovery program on novel non-hormonal contraceptive medicines 

Nuvisan receives $9.6 million grant

Nuvisan has received a grant from the Gates Foundation for a multi-target drug discovery program.

learn more

Other stories

Contact us

Nuvisan is committed to protecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:
You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Talk to us

talk icon
+49 731 9840 0 

Our locations

location icon

Neu-Ulm (headquarters)

Wegenerstrasse 13

89231 Neu-Ulm

Germany

Berlin

Muellerstrasse 178

13353 Berlin

Germany

Sophia Antipolis

2400 route des Colles

06410 Biot

France

Grafing

Am Feld 32

85567 Grafing

Germany

Waltrop

Im Wirrigen 25

45731 Waltrop

Germany

For concerns about pharmaceuticals or adverse drug-related events, contact us at: complaints@nuvisan.com